In vivo delivery of peptides and Toll-like receptor ligands by mannose-functionalized polymeric nanoparticles induces prophylactic and therapeutic anti-tumor immune responses in a melanoma model

Journal of Controlled Release

Volumn 198, Issue , 2015, Pages 91-103

  Silva, Joana M ^a,b   Zupancic, Eva ^a   Vandermeulen, Gaëlle ^b   Oliveira, Vanessa G ^c   Salgado, Ana ^a   Videira, Mafalda ^a   Gaspar, Manuela ^a   Graca, Luis ^c   Préat, Véronique ^b   Florindo, Helena F ^a  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Antigen presenting cells; Cancer vaccine; Mannose receptor targeting; Melanoma; Nanoparticles; PLGA; TLR

Indexed keywords

ALIPHATIC COMPOUNDS; ANTIGENS; DERMATOLOGY; DISEASES; FUNCTIONAL POLYMERS; GROWTH RATE; LIGANDS; NANOPARTICLES; ONCOLOGY; TUMORS; VACCINES;

ANTIGEN PRESENTING CELLS; CANCER VACCINE; MANNOSE RECEPTORS; MELANOMA; PLGA;

IMMUNE SYSTEM;

CANCER VACCINE; CPG; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2C; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MANNOSE; MANNOSE RECEPTOR; MELANOMA ANTIGEN; NANOPARTICLE; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; CPG ODN 1826; CYTOKINE; GRANZYME; LIGAND; MELAN A; MELANOCYTE PROTEIN PMEL 17; OLIGODEOXYRIBONUCLEOTIDE; OVALBUMIN; PEPTIDE; POLYMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNIZATION; CANCER PREVENTION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEMALE; IN VIVO STUDY; MALE; MELANOMA; MOUSE; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR VOLUME; ZETA POTENTIAL; ANIMAL; BLOOD; C57BL MOUSE; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; GP100 MELANOMA ANTIGEN; GRANZYMES; IMMUNOGLOBULIN G; LIGANDS; MALE; MANNOSE; MART-1 ANTIGEN; MELANOMA; MICE, INBRED C57BL; MICE, TRANSGENIC; NANOPARTICLES; OLIGODEOXYRIBONUCLEOTIDES; OVALBUMIN; PEPTIDES; POLY I-C; POLYMERS; TOLL-LIKE RECEPTORS; TUMOR BURDEN;

EID: 84918557500     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.11.033     Document Type: Article

References (55)

1. J. Begley, and A. Ribas Targeted therapies to improve tumor immunotherapy Clin. Cancer Res. 14 14 2008 4385 4391
2. R. Arens, and S.P. Schoenberger Plasticity in programming of effector and memory CD8 + T cell formation Immunol. Rev. 235 1 2010 190 205
3. D.J. Shedlock, and H. Shen Requirement for CD4 T cell help in generating functional CD8 T cell memory Science 300 5617 2003 337 339
4. N. Kadowaki Dendritic cells: a conductor of T cell differentiation Allergol. Int. 56 3 2007 193 199
5. A.K. Palucka, H. Ueno, J. Fay, and J. Banchereau Dendritic cells: a critical player in cancer therapy? J. Immunother. 31 9 2008 793 805
6. T. Kambayashi, and T.M. Laufer Atypical MHC class II-expressing antigen-presenting cells: can anything replace a dendritic cell? Nat. Rev. Immunol. 14 11 2014 719 730 (Novembro de)
7. T. Kawai, and S. Akira TLR signaling 19 1 2007 24 32
8. L. Vujanovic, and L.H. Butterfield Melanoma cancer vaccines and anti tumor T cell responses J. Cell. Biochem. 102 2 2007 301 310
9. K. Breckpot, M. Dullaers, A. Bonehill, S. van Meirvenne, C. Heirman, and C. de Greef Lentivirally transduced dendritic cells as a tool for cancer immunotherapy J. Gene Med. 5 8 2003 654 667 ((Agosto de))
10. K. Breckpot, and D. Escors Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification Endocr. Metab. Immune Disord. Drug Targets 9 4 2009 328 343 (Dezembro de)
11. S. Hamdy, P. Elamanchili, A. Alshamsan, O. Molavi, T. Satou, and J. Samuel Enhanced antigen specific primary CD4 + and CD8 + responses by codelivery of ovalbumin and Toll like receptor ligand monophosphoryl lipid A in poly (d, l lactic co glycolic acid) nanoparticles J. Biomed. Mater. Res. A 81 3 2007 652 662
12. B. Slütter, and W. Jiskoot Dual role of CpG as immune modulator and physical crosslinker in ovalbumin loaded N-trimethyl chitosan (TMC) nanoparticles for nasal vaccination J. Control. Release 148 1 2010 117 121
13. H.F. Florindo, S. Pandit, L. Gonçalves, M. Videira, O. Alpar, and A.J. Almeida Antibody and cytokine-associated immune responses to S. equi antigens entrapped in PLA nanospheres Biomaterials 30 28 2009 5161 5169
14. C. Clawson, C.T. Huang, D. Futalan, D. Martin Seible, R. Saenz, and M. Larsson Delivery of a peptide via poly (d, l-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell-stimulatory capacity Nanomedicine 6 5 2010 651 661
15. E. Macho Fernandez, J. Chang, J. Fontaine, E. Bialecki, F. Rodriguez, and E. Werkmeister Activation of invariant natural killer T lymphocytes in response to the α-galactosylceramide analogue KRN7000 encapsulated in PLGA-based nanoparticles and microparticles Int. J. Pharm. 423 1 2012 45 54
16. E. Schlosser, M. Mueller, S. Fischer, S. Basta, D.H. Busch, and B. Gander TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses Vaccine 26 13 2008 1626 1637
17. M.F. Bachmann, and G.T. Jennings Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns Nat. Rev. Immunol. 10 11 2010 787 796
18. D.N. Nguyen, K.P. Mahon, G. Chikh, P. Kim, H. Chung, and A.P. Vicari Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery Proc. Natl. Acad. Sci. U. S. A. 109 14 2012 E797 E803
19. F. Danhier, E. Ansorena, J.M.J. Silva, R. Coco, A. Le Breton, and V. Préat PLGA-based nanoparticles: an overview of biomedical applications J. Control. Release 161 2 2012 505 522
20. J. Panyam, and V. Labhasetwar Biodegradable nanoparticles for drug and gene delivery to cells and tissue Adv. Drug Deliv. Rev. 55 3 2003 329 347
21. R.A. Jain, C.T. Rhodes, A.M. Railkar, A.W. Malick, and N.H. Shah Controlled release of drugs from injectable in situ formed biodegradable PLGA microspheres: effect of various formulation variables Eur. J. Pharm. Biopharm. 50 2 2000 257 262
22. E. Fernandez-Megia, R. Novoa-Carballal, E. Quiñoá, and R. Riguera Conjugation of bioactive ligands to PEG-grafted chitosan at the distal end of PEG Biomacromolecules 8 3 2007 833 842
23. Y. Van Kooyk C-type lectins on dendritic cells: key modulators for the induction of immune responses Biochem. Soc. Trans. 36 Pt 6 2008 1478 1481
24. J.M. Silva, M. Videira, R. Gaspar, V. Préat, and H.F. Florindo Immune system targeting by biodegradable nanoparticles for cancer vaccines J. Control. Release 168 2 2013 179 199
25. H. Freichels, V. Pourcelle, C.S. Le Duff, J. Marchand Brynaert, and C. Jérôme "Clip" and "click" chemistries combination: toward easy PEGylation of degradable aliphatic polyesters Macromol. Rapid Commun. 32 7 2011 616 621
26. P. Vangeyte, B. Leyh, M. Heinrich, J. Grandjean, C. Bourgaux, and R. Jérôme Self-assembly of poly(ethylene oxide)-b-poly(epsilon-caprolactone) copolymers in aqueous solution Langmuir 20 20 2004 8442 8451
27. J. Rieger, H. Freichels, A. Imberty, J.L. Putaux, T. Delair, and C. Je ro me Polyester nanoparticles presenting mannose residues: toward the development of new vaccine delivery systems combining biodegradability and targeting properties Biomacromolecules 10 3 2009 651 657
28. G. Poste, J. Doll, I.R. Hart, and I.J. Fidler In vitro selection of murine B16 melanoma variants with enhanced tissue-invasive properties Cancer Res. 40 5 1980 1636 1644 (Maio de)
29. M. Garinot, V. Fiévez, V. Pourcelle, F. Stoffelbach, A. Des Rieux, and L. Plapied PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination J. Control. Release 120 3 2007 195 204
30. H. Florindo, S. Pandit, L. Lacerda, L. Gonçalves, H. Alpar, and A. Almeida The enhancement of the immune response against S. equi antigens through the intranasal administration of poly-caprolactone-based nanoparticles Biomaterials 30 5 2009 879 891
31. M. Adamina, M. Bolli, F. Albo, A. Cavazza, P. Zajac, and E. Padovan Encapsulation into sterically stabilised liposomes enhances the immunogenicity of melanoma-associated Melan-A/MART-1 epitopes Br. J. Cancer 90 1 2004 263 269
32. A.M. Hafner, B. Corthesy, M. Textor, and H.P. Merkle Tuning the immune response of dendritic cells to surface-assembled poly(I:C) on microspheres through synergistic interactions between phagocytic and TLR3 signaling Biomaterials 32 10 2011 2651 2661
33. E. Kinoshita-Kikuta, E. Kinoshita, and T. Koike Separation and identification of four distinct serine-phosphorylation states of ovalbumin by phos-tag affinity electrophoresis Electrophoresis 33 5 2012 849 855 (Março de)
34. S.D. Xiang, A. Scholzen, G. Minigo, C. David, V. Apostolopoulos, and P.L. Mottram Pathogen recognition and development of particulate vaccines: does size matter? Methods 40 1 2006 1 9
35. C.D. Platt, J.K. Ma, C. Chalouni, M. Ebersold, H. Bou-Reslan, and R.A.D. Carano Mature dendritic cells use endocytic receptors to capture and present antigens Proc. Natl. Acad. Sci. U.S.A. 107 9 2010 4287 4292
36. M. Kalariya, S. Ganta, and M. Amiji Multi-compartmental vaccine delivery system for enhanced immune response to gp100 peptide antigen in melanoma immunotherapy Pharm. Res. 29 12 2012 3393 3403
37. W.J. Lesterhuis, J.B. Haanen, and C.J. Punt Cancer immunotherapy - revisited Nat. Rev. Drug Discov. 10 8 2011 591 600
38. H. Benlalam, N. Labarrière, B. Linard, L. Derré, E. Diez, and M.C. Pandolfino Comprehensive analysis of the frequency of recognition of melanoma associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy Eur. J. Immunol. 31 7 2001 2007 2015
39. G. Gautier, M. Humbert, F. Deauvieau, M. Scuiller, J. Hiscott, and E.E.M. Bates A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells J. Exp. Med. 201 9 2005 1435 1446
40. G. Schreibelt, J. Tel, K.H. Sliepen, D. Benitez-Ribas, C.G. Figdor, and G.J. Adema Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy Cancer Immunol. Immunother. 59 10 2010 1573 1582
41. R. Schumacher, M. Amacker, D. Neuhaus, R. Rosenthal, C. Groeper, and M. Heberer Efficient induction of tumoricidal cytotoxic T lymphocytes by HLA-A0201 restricted, melanoma associated, L (27) Melan-A/MART-1 (26-35) peptide encapsulated into virosomes in vitro Vaccine 23 48-9 2005 5572
42. S.P. Kasturi, I. Skountzou, R.A. Albrecht, D. Koutsonanos, T. Hua, and H.I. Nakaya Programming the magnitude and persistence of antibody responses with innate immunity Nature 470 7335 2011 543 547
43. S. Hamdy, O. Molavi, Z. Ma, A. Haddadi, A. Alshamsan, and Z. Gobti Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8 + T cell-mediated anti-tumor immunity Vaccine 26 39 2008 5046 5057
44. J.M.M. Gómez, S. Fischer, N. Csaba, T.M. Kündig, H.P. Merkle, and B. Gander A protective allergy vaccine based on CpG- and protamine-containing PLGA microparticles Pharm. Res. 24 10 2007 1927 1935
45. S.A. Linehan, L. Martínez-Pomares, P.D. Stahl, and S. Gordon Mannose receptor and its putative ligands in normal murine lymphoid and nonlymphoid organs: in situ expression of mannose receptor by selected macrophages, endothelial cells, perivascular microglia, and mesangial cells, but not dendritic cells J. Exp. Med. 189 12 1999 1961 1972 (21 de Junho de)
46. C. Schliehe, C. Redaelli, S. Engelhardt, M. Fehlings, M. Mueller, and N. van Rooijen CD8- dendritic cells and macrophages cross-present poly(d, l-lactate-co-glycolate) acid microsphere-encapsulated antigen in vivo J. Immunol. 187 5 2011 2112 2121 10.4049/jimmunol.1002084 ([Internet]. 1 de Setembro de 2011 [citado 19 de Novembro de 2014], Obtido de)
47. V. Fievez, L. Plapied, A. Des Rieux, V. Pourcelle, H. Freichels, and V. Wascotte Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination Eur. J. Pharm. Biopharm. 73 1 2009 16 24
48. L.Z. He, A. Crocker, J. Lee, J. Mendoza-Ramirez, X.T. Wang, and L.A. Vitale Antigenic targeting of the human mannose receptor induces tumor immunity J. Immunol. 178 10 2007 6259 6267
49. M.J. Barnden, J. Allison, W.R. Heath, and F.R. Carbone Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements Immunol. Cell Biol. 76 1 1998 34 40
50. S. Leung, D. Smith, A. Myc, J. Morry, and J.R. Baker OT-II TCR transgenic mice fail to produce anti-ovalbumin antibodies upon vaccination Cell. Immunol. 282 2 2013 79 84
51. J.W. Yewdell, and J.R. Bennink Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses Annu. Rev. Immunol. 17 1999 51 88
52. Y.-R. Lee, Y.-H. Lee, S.-A. Im, I.-H. Yang, G.W. Ahn, and K. Kim Biodegradable nanoparticles containing TLR3 or TLR9 agonists together with antigen enhance MHC-restricted presentation of the antigen Arch. Pharm. Res. 33 11 2010 1859 1866
53. G.W. Stone, S. Barzee, V. Snarsky, C. Santucci, B. Tran, and R. Langer Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like receptor agonists as a treatment for melanoma PLoS One 4 10 2009 e7334
54. C. Bourgeois, H. Veiga Fernandes, A.M. Joret, B. Rocha, and C. Tanchot CD8 lethargy in the absence of CD4 help Eur. J. Immunol. 32 8 2002 2199 2207
55. Kennedy R. Celis E. Multiple roles for CD4 + T cells in anti tumor immune responses Immunol. Rev. 2008 222 1 129-144.